Outcome of Azacitidine Therapy in Acute Myeloid Leukemia Is Not Improved by Concurrent Vorinostat Therapy but Is Predicted by a Diagnostic Molecular Signature

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-17-1423
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Therapy of Acute Myeloid Leukemia

2012English

SHIP1 Is Targeted by miR-155 in Acute Myeloid Leukemia

Oncology Reports
MedicineCancer ResearchOncology
2014English

Therapy-Related Myelodysplasia and Acute Myeloid Leukemia

Seminars in Oncology
OncologyHematology
2013English

RAS Mutation in Acute Myeloid Leukemia Is Associated With Distinct Cytogenetic Subgroups but Does Not Influence Outcome in Patients Younger Than 60 Years

Blood
BiochemistryImmunologyCell BiologyHematology
2005English

STAT3β Is a Tumor Suppressor in Acute Myeloid Leukemia

Intrinsic Activity
2019English

Strategy for Incorporating Molecular and Cytogenetic Markers Into Acute Myeloid Leukemia Therapy

Journal of the National Comprehensive Cancer Network : JNCCN
MedicineOncology
2008English

“Epigenetic” Modification as Therapy for Acute Myeloid Leukemia

Cancer
Cancer ResearchOncology
2017English

Targeted Therapy in Acute Myeloid Leukemia: Aim With Caution

International Journal of Hematologic Oncology
OncologyHematologyPharmacology
2012English

Clofarabine Combinations as Acute Myeloid Leukemia Salvage Therapy

Cancer
Cancer ResearchOncology
2008English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy